More recently, growing regulatory acceptance, rising demand from payers and physicians, and increasing familiarity with digital and analytics have enabled some companies to derive much broader benefits from RWE. Pharma companies have been using real-world evidence for decades to inform their decision making, respond to requests from external stakeholders, and improve their therapies’ market positioning. Given the significant disruption to RCTs and the need to rapidly understand burden by patient phenotype, and potential therapies for COVID-19, RWE is more in the spotlight than ever. Treatment to the right patient at the right time, measuring outcomes, and demonstrating the value of interventions. In this changing environment, insights from real-world evidence are becoming more important in getting the right providers are angling to gain privileged status with them and patients are taking more ownership of their own outcomes. See, for instance, “Amgen and Harvard Pilgrim agree to first cardiovascular outcomes-based refund contract for Repatha (evolocumab),” Amgen, May 2, 2017, “Harvard Pilgrim signs outcomes-based contract with AstraZeneca for Symbicort,” Harvard Pilgrim, April 18, 2018,. Payers are gradually shifting to outcomes-based contracts 1 From table stakes to high stakesĬost and competitive pressures, scientific advances, digital-savvy stakeholders, progressive regulatory shifts, and the increasing breadth and interoperability of data and technologies are among many trendsĭriving participants in the healthcare ecosystem to intensify their focus on value and patient outcomes. Real-world evidence helps us understand how patient characteristics and behaviors affect health outcomes. For any company considering deploying advanced RWE analytics, success will depend on building the right framework and capabilities.
![convert enterprise value to equity value convert enterprise value to equity value](https://2.bp.blogspot.com/-wbkhxCKAg1g/Uc3zSu9IpJI/AAAAAAAAAfs/TH-z_WDP8nY/w1200-h630-p-k-no-nu/balsheet.jpg)
![convert enterprise value to equity value convert enterprise value to equity value](https://cdn.wallstreetmojo.com/wp-content/uploads/2016/11/2016-11-16_14-20-20.jpg)
It can help us understand how patient characteristics and behaviors affect health outcomes-thereby helping to predict the progression of a disease, a patient’s responses to a therapy, or the risk of adverse events, for instance-while also increasing the efficiency of R&D investments and accelerating time to market. Real-world evidence (RWE) has been in use for decades, but recent advances in digital and advanced analytics allow it to be employed in new ways. As the healthcare industry focuses increasingly on outcomes, pharma companies are looking to sources beyond randomized clinical trials (RCTs) to measure and demonstrate the value they bring.